W.O.M. World of Medicine AG

euro adhoc: W.O.M. World of Medicine AG
WORLD OF MEDICINE will exceed sales and revenue goals for Fiscal Year 2006, and increase planning for 2007

-------------------------------------------------------------------------------- Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. -------------------------------------------------------------------------------- 11.01.2007 (Berlin, January 11, 2007) Medical device manufacturer WORLD OF MEDICINE will clearly exceed its goal of a slight revenue increase for fiscal year 2006, despite implementation of portfolio streamlining, with total sales of approximately EUR30.8 million (plus 5.8%, 2005: EUR29.1 million). The cost savings achieved through the "Profit" project were likewise higher than expected. This leads to a significant improvement in operating income, and an increase in the pre-tax sales yield. Based on the revised projection, which is based on actual figures as of the end of November, and which takes the preliminary figures for December into account, the Management Board is now forecasting a gross margin of 45% (2005: 31%, plan 2006: 39%). The anticipated pre-tax sales yield equals approximately 7% (2005: -13%, plan 2006: 3%) For 2007, the Management Board now expects an increase in sales equivalent to the growth in the market segment (approximately 5%) and a pre-tax sales yield of approximately 8% (prior: 4%). The Management Board WORLD OF MEDICINE and its technologies are paving the way in Minimally Invasive Surgery - or MIS® for short. The device manufacturer focuses on private label business and markets its products through renowned major medical technology firms. WORLD OF MEDICINE, a well-positioned international firm, exports more than 70 % of its products, and will soon profit from the strong growth markets outside of Europe. More than 40 % of its sales are transacted in the U.S., the world’s largest medical technology market. In addition to this, WORLD OF MEDICINE has made well-timed investments in the new markets opening in Asia, especially China. Its 30 years of experience in MIS® are substantiated by the long standing relationships with private label partners and more than 40 FDA approvals. A 50% global market share in the Flow&Fluid business division, and more than 50 patents underscore its strong technology and product portfolio. The Stock of WORLD OF MEDICINE (ISIN DE 0006637390) is listed in the Prime Standard at the Frankfurt stock exchange and in the German Entrepreneurial Index (GEX). end of announcement euro adhoc 11.01.2007 11:02:21 -------------------------------------------------------------------------------- ots Originaltext: W.O.M. World of Medicine AG Im Internet recherchierbar: http://www.presseportal.ch Further inquiry note: Stefanie Gehrke IR / Verena Zahn Assistant to CFO Tel.: +49 (0)30 39981 566 / +49 (0)30 39981 642 stefanie.gehrke@womcorp.com / verena.zahn@womcorp.com Branche: Pharmaceuticals ISIN: DE0006637390 WKN: 663739 Index: CDAX, Prime All Share, Technologie All Share Börsen: Frankfurter Wertpapierbörse / regulated dealing/prime standard Börse Berlin-Bremen / free trade Hamburger Wertpapierbörse / free trade Baden-Württembergische Wertpapierbörse / free trade Börse Düsseldorf / free trade Bayerische Börse / free trade

Das könnte Sie auch interessieren: